BRAF and melanoma: Nowadays, there are several therapeutic options for stage III BRAF mutated or wild-type melanoma in the adjuvant setting, but none of these have shown a statistically significant OS benefit (although dabrafenib/trametinib showed an important trend in favour of combination therapy over placebo), and all of these therapies have a toxicity profile that requires careful consideration [4–6].